Molecular Cancer Research publishes articles featuring novel, basic cancer research discoveries that prioritize broad molecular and cellular processes. Areas of emphasis include cell cycle and ...

Interested individuals should prepare and submit an application to Christine Battle, Publisher and Vice President, Scientific Publications, AACR via email ([email protected]) by Monday, ...

Search for other works by this author on: ...

Adding the PD-1 inhibitor pembrolizumab to chemoradiotherapy for high-risk, locally advanced cervical cancer significantly improves patients’ overall survival compared to treatment with CRT alone.

Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to ...

University of Nebraska Medical Center, Omaha, NE, ...

According to the phase IIIb/IV DESTINYBreast-12 Trial, the results of which were presented at the European Society for Medical Oncology 2024 Congress in Barcelona, Spain, and concurrently published, ...

Which manuscripts qualify for the simultaneous publication opportunity? Any manuscripts on the same topic as the author’s submitted abstract, and that are submitted by the deadlines noted below, will ...

Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...

The FDA approved the PD1 inhibitor atezolizumab plus hyaluronidase (Tecentriq Hybreza; Genentech), which helps the drug move into tissues, as a subcutaneous injection for the same adult indications as ...

According to data presented at the ESMO Congress 2024, being held from September 13–17 in Barcelona, Spain, for patients with advanced renal cell carcinoma, oncologists should avoid prescribing ...